Tag: Survival
Time to Treatment Not Tied to Worse Outcomes in Young Colorectal Cancer Patients
Findings seen for both overall survival and cause-specific survival
Living in Disadvantaged Neighborhood Shortens Breast Cancer Survival
Findings seen after adjusting for sociodemographics, comorbidity, breast cancer risk factor, access to care, tumor, and guideline-concordant treatment
Adding Pembrolizumab to Chemo Improves Survival in Endometrial Cancer
Addition of pembrolizumab to paclitaxel plus carboplatin yields longer progression-free survival in advanced, recurrent disease
Adding Dostarlimab Improves Progression-Free Survival in Endometrial Cancer
Dostarlimab plus carboplatin-paclitaxel linked to increased progression-free survival overall and in dMMR-MSI-H population
Frequent Social Activity Tied to Longer Survival in Older Adults
Threshold effect seen with meaningful benefit for participating in social activity almost every day
Survival Rate Lower for Surgery Nine Weeks or More After Breast Cancer Diagnosis
Younger age, uninsured or Medicaid status, and lower household income were associated with longer times to surgery
SBRT Well Tolerated, Effective for Primary Lung Neuroendocrine Tumor
At three, six, and nine years, overall survival was 64, 43, and 26 percent and progression-free survival was 88, 78, and 78 percent, respectively
Study Looks at Clonal Hematopoiesis in Pediatric Cancer Survivors
Clonal hematopoiesis occurs more often in pediatric cancer survivors; is associated with exposures to alkylating agents, radiation, bleomycin
Outcomes for R-CHOP Worse in Morning for Female Patients With Lymphoma
Progression-free, overall survival significantly lower for female patients receiving chemo mostly in morning
Body Mass Index Tied to Multiple Myeloma Survival
Decreased survival seen for both underweight and severe obesity in newly diagnosed patients
